Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed Refractory Multiple Myeloma

Conditions

Relapsed Refractory Multiple Myeloma

Trial Timeline

Apr 1, 2019 → Dec 31, 2024

NCT ID

NCT03732703

About Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide

Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide is a phase 1/2 stage product being developed by Eli Lilly for Relapsed Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT03732703. Target conditions include Relapsed Refractory Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03732703	Phase 1/2	Completed	Apr 1, 2019	Dec 31, 2024	Relapsed Refractory Multiple Myeloma

Competing Products

20 competing products in Relapsed Refractory Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
agenT-797	MiNK Therapeutics	Phase 1	25
VIP152 + BTKi	Vincerx Pharma	Phase 1	25
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	77
AC220	Daiichi Sankyo	Phase 1	33
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Linsitinib	Astellas Pharma	Phase 2	52
AGS67E	Astellas Pharma	Phase 1	33
Mitoxantrone Hydrochloride Liposome & Enlonstobart	Sun Pharmaceutical	Phase 1/2	41
Lenvatinib	Eisai	Phase 2	52
Tazemetostat	Eisai	Phase 2	52
Tazemetostat	Eisai	Phase 1	33
Eribulin mesylate	Eisai	Phase 2	52
ME-401	Kyowa Kirin	Phase 1	33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6	Kyowa Kirin	Phase 1	33
Mogamulizumab	Kyowa Kirin	Phase 2	52
ONO-4685	Ono Pharmaceutical	Phase 1	33
ONO-4685	Ono Pharmaceutical	Phase 1	33
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved